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2

TRANSDERMAL DELIVERY OF OPIOID
ANTAGONIST PRODRUGS

a mammal. Also, hereinafter, the term “physiological
hydrolysis or physiologically hydrolyZable, or physiologi
cally hydrolyZing” means replacement of R, or R and R1 in
prodrugs
infra With a hydrogen atom as the prodrug
passes through the skin. In addition, hereinafter, the term
“opioid antagonist” refers to various substances that are able
to block the receptors for opiates and thus prevent the

BACKGROUND OF THE INVENTION

1. Technical Field
The present invention relates to a composition, a method

euphoric effects of, eg morphine and alcohol. Furthermore,

and an apparatus for transdermally delivering an effective

amount of opioid antagonists derived from prodrugs for
treatment of eating disorders, narcotic dependence and alco
holism. Alternatively, the present invention relates to a
composition, a method and an apparatus for transdermally
delivering an effective amount of an opioid antagonist
derived from pro-drugs and an effective amount of an opioid

agonist for treatment of pain.

10

in the prodrugs
infra.
The apparatus for transdermal delivery comprises: a pro
drug permeable adhesive layer having a ?rst surface and a
second surface on a substrate; a prodrug layer, having an
15

2. Related Art

layer and an opioid may be operatively attached to the ?rst
surface of the adhesive layer. The substrate may be mam

one is currently available as NaltreXone Hydrochloride in a

malian such as human skin. The prodrug may be a derivative

50-mg oral tablet (ReVia®).

of naltreXone, nalbuphine, nalorphine, naloXone, nalmefene,
cyclaZocine, levallorphan, cyclorphan, oXilorphan, and

There is a need to accurately deliver effective amounts of
opioid antagonists such as NaltreXone in a manner that

pentaZocine, described infra Which are permeable through

encourages voluntary compliance When such opioid antago
25

dosage form is applied. Alternatively, opioid(s) Which are

The present invention provides a composition, a method
and an apparatus for transdermally delivering an effective

amount of opioid antagonists derived from prodrugs for

35

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 depicts a front cross-sectional vieW of a transder

mal drug delivery apparatus on a substrate, in accordance
With preferred embodiments of the present invention.
FIG. 2 depicts FIG. 1 after an impermeable barrier has

been formed in the transdermal drug delivery apparatus.
FIG. 3 is a graph shoWing NTX and Valeroyl-NTX

the dosage form and also permeable to the skin to Which the

permeable through the adhesive layer and are also perme
able through the skin may be operatively attached to the
adhesive layer. By the term “opioid” is meant any natural or
synthetic opioid analgesic or other narcotic analgesic or
mixtures thereof. Some eXamples of suitable opioids useful
according to this invention are alfentanil, allylprodine,

SUMMARY OF THE INVENTION

treatment of narcotic dependence and alcoholism. In
addition, the present invention relates to a composition, a
method and an apparatus for transdermally delivering an
effective amount of an opioid antagonist derived from
prodrugs and an effective amount of an opioid agonist for
treatment of pain.

eXposed surface, operatively attached to a ?rst surface of the
adhesive layer; and a prodrug impermeable polymer ?lm on
the eXposed surface of the prodrug layer and on a second

surface of the adhesive layer. Alternatively, the prodrug

Opioid antagonists such as NaltreXone may be used for
treatment of narcotic dependence and alcoholism. NaltreX

nists are used for the treatment of narcotic dependence and
alcoholism.

hereinafter the term “prodrug” refers to a drug that has been
chemically modi?ed by substitution of an R or R1 group as

45

accumulation over time as measured in vitro.

FIG. 4 is a bar graph shoWing the effect of age, seX or

alphaprodine, anileridine, benZylmorphine, beZitramide,
buprenorphine, butorphanol, clonitaZene, codeine,
desomorphine, deXtromoramide, deZocine, diampromide,
dihydrocodeine, dihydromorphine, dimenoXadol,
dimepheptanol, dimethylthiambutene, dioXaphetyl butyrate,
dipipanone, eptaZocine, ethoheptaZine,
ethylmethylthiambutene, ethylmorphine, etonitaZene,
fentanyl, hydrocodone, hydromorphone, hydroXypethidine,
isomethadone, ketobemidone, levorphanol, lofentanil,
meperidine, meptaZionl, metaZocine, methadone, metopon,
morphine, myrophine, nalbuphine, narceine, nicomorphine,
norlevorphanol, normethadone, normorphine, norpipanone,
opium, oXycodone, oXymorphone, papaveretum,
pentaZocine, phenadoXone, phenaZocine, phenoperidine,
piminodine, piritramide, proheptaZine, promedol,
properidine, propiram, propoXyphene, sufentanil, tilidine,
fentanyl and pharmaceutically acceptable salts thereof and

condition of skin sample (fresh or froZen) on NTX ?uX.
FIG. 5 is a bar graph shoWing the lag time in ?uX for

buprenorphine, and pharmaceutically acceptable salts

NTX, Valeroyl-NTX and Hep-NTX.

thereof. Alternatively, morphine derivatives that are perme

DETAILED DESCRIPTION OF THE
INVENTION

mixtures thereof. The most preferred opioids are fentanyl,
able to the skin in analgetically effective amounts such as

those disclosed by Bundgaard et al. in 1999, in US. Pat. No.
55

5,908,846, herein incorporated by reference, may be opera
tively attached to the ?rst surface 17 of the adhesive layer
20.

The present invention relates to an apparatus, a method

and a composition for transdermally delivering an effective

amount of opioid antagonists derived from prodrugs for

FIG. 1 illustrates a front cross-sectional vieW of a trans

treatment of narcotic dependence and alcoholism.
Hereinafter, the term “effective amount” is an optimal trans
dermally delivered dose of prodrug, determined by one

dermal drug delivery apparatus 1 on a substrate 5, in
accordance With preferred embodiments of the present
invention. The substrate 5 includes substrate material such

skilled in the art, needed for treating narcotic dependence
and alcoholism. Also hereinafter, the term “transdermally

apparatus 1 comprises: a prodrug permeable adhesive layer

as mammalian or human skin. The transdermal delivery

delivering or delivery” means applying and affixing a skin

permeable prodrug to the skin, Wherein the prodrug under

goes physiological hydrolysis, resulting in introducing the
hydrolyZed prodrug into the systemic circulatory system of

20, having a surface 3, formed on the substrate 5, Wherein
65

the prodrug permeable adhesive layer 20 includes adhesive
materials; a prodrug layer 15 formed on the surface 3 of the

prodrug permeable adhesive layer 20, Wherein the prodrug

US 6,569,449 B1
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copolymers, ethylene/ethylacrylate copolymers, ethylene/

3
layer 15 has an exposed surface 23, and Wherein the prodrug
layer 15 comprises prodrug materials that diffuse into the

vinyl acetate copolymers, silicone elastomers, medical

prodrug permeable adhesive layer 20, and a polymer ?lm 2,

grade polydimethylsiloxanes, neoprene rubber,
polyisobutylene, chlorinated polyethylene, polyvinyl
chloride, vinylchloride-vinyl acetate copolymer, poly

formed on the exposed surface 23 of the prodrug layer 15,
Wherein the polymer ?lm may be made from materials that
are impermeable to the prodrug. The adhesive layer 20 may
be prepared from polymers and copolymers may be selected
from the group consisting of, but not limited to, butyl

methacrylate polymer (hydrogel), polyvinylidene chloride,
poly(ethylene terephthalate), butyl rubber, epichlorohydrin

acrylate, ethyl acrylate, ethyl hexyl acrylate, vinylacetate/
ethylene acrylate and mixtures thereof. The prodrug layer 15
includes inter alia prodrug materials derived from an effec
tive amount of opioid antagonists such as naltrexone,

nalbuphine, nalorphine, naloxone, nalmefene, cyclaZocine,
levallorphan, cyclorphan, oxilorphan, and pentaZocine, or
combinations thereof. Alternatively, the prodrug layer 15

15

may include a permeation enhancer material in addition to

the prodrug material, Wherein the permeation enhancer
material and the prodrug material are mixed to form a

rubbers, ethylene-vinyl alcohol copolymer, ethyleneviny
loxyethanol copolymer; silicone copolymers, polysiloxane
polycarbonate copolymers, polysiloxane-polyethyleneoxide
copolymers, polysiloxane-polymethacrylate copolymers,
polysiloxane-polymethacrylate copolymers, polysiloxane
alkylene copolymers polysiloxane-ethylene copolymers,
polysiloxane-alkylenesilane copolymers, polysiloxaneethyl
enesilane copolymers, cellulose polymers, methyl cellulose,
ethyl cellulose, hydroxypropyl methyl cellulose, cellulose
esters, polycarbonates, polytetra?uoroethylene, starches,

solution, suspension, gel or matrix having the effective

gelatins, natural gums, synthetic gums, and combinations

amount of prodrug. The device may be any of the general
types knoWn in the art including adhesive matrix and

reservoir type transdermal delivery systems. The permeation

thereof. Aprodrug layer 16 has been formed on a surface 19
of a portion 13 of the prodrug permeable adhesive 20 and a
prodrug layer 30 has been formed on a surface 17 of a

enhancer material may include, but is not limited to, lauric

remaining portion 14 of the prodrug permeable adhesive

acid, oleic acid, linoleic acid, octanol, decanol, lauryl

alcohol, myristyl alcohol, myristoleyl alcohol, palmitoleyl
alcohol, oleyl alcohol, linolenyl alcohol, linolyl alcohol,
elaidyl alcohol, vaccenyl alcohol, petroselinyl alcohol,
petroselaidyl alcohol, methyl caproate, propyl caproate,
hexyl acetate, methyl heptylate, pentyl heptylate, heptyl
acetate, heptyl caproate, methyl caprylate, propyl caprylate,
octyl acetate, octyl butylate, methyl caprate, ethyl caprate,
hexyl caprate, methyl pelargonate, butyl pelargonate, lauryl
acetate, lauryl butylate, methyl laurate, ethyl laurate, iso
propyl laurate, hexyl laurate, methyl myristate, ethyl
myristate, isopropyl myristate, pentadecyl acetate, methyl
palmitate, ethyl palmitate, isopropyl palmitate, hexadecyl
acetate, methyl oleate, ethyl oleate, butyl oleate, dimethyl
adipate, disopropyl adipate, disobutyl adioate,
dimethylmaleate, diisopropyl malate, dibutyl malate,

layer 20. The prodrug layers 16 and 30 include inter alia
25

opioid antagonists such as naltrexone, nalbuphine,

nalorphine, naloxone, nalmefene, cyclaZocine, levallorphan,
cyclorphan, oxilorphan, and pentaZocine or combinations
thereof, described infra as prodrugs.
Alternatively,
effective amounts of opioid antagonists such as naltrexone,

nalbuphine, nalorphine, naloxone, nalmefene, cyclaZocine,
levallorphan, cyclorphan, oxilorphan, and pentaZocine or
combinations thereof may be operatively attached to the ?rst
35

surface 17 of the adhesive layer 20. Alternatively, the
prodrug layers 16 and 30 may include a mixture containing
a permeation enhancer material described supra and an

effective amount of the prodrug material. Alternatively,

opioid(s) Which, are permeable through the adhesive layer
and are also permeable through the skin may be operatively
attached to the ?rst surface 17 of the adhesive layer 20.
Alternatively, morphine derivatives that are permeable to the

dihexyl maleate, ethyl alcohol and mixtures thereof. The
polymer ?lm 2 may be made from materials including

polyethylene, polypropylene, ethylene/propylene
copolymers, ethylene/ethylacrylate copolymers, ethylene/

skin in analgetically effective amounts such as those dis

vinyl acetate copolymers, silicone elastomers, medical

grade polydimethylsiloxanes, neoprene rubber,
polyisobutylene, chlorinated polyethylene, polyvinyl
chloride, vinylchloride-vinyl acetate copolymer, poly

prodrug materials derived from an effective amount of

45

closed by Bundgaard et al. in US. Pat. No. 5,908,846, supra,
may be operatively attached to the ?rst surface 17 of the

adhesive layer 20.
Another embodiment of the present invention is a method

methacrylate polymer (hydrogel), polyvinylidene chloride,
poly(ethylene terephthalate), butyl rubber, epichlorohydrin

comprising the step of: transdermally delivering an effective

rubbers, ethylene-vinyl alcohol copolymer, ethyleneviny
loxyethanol copolymer; silicone copolymers, polysiloxane

consisting of naltrexone, nalbuphine, nalorphine, naloxone,

polycarbonate copolymers, polysiloxane-polyethyleneoxide
copolymers, polysiloxane-polymethacrylate copolymers,
polysiloxane-polymethacrylate copolymers, polysiloxane
alkylene copolymers polysiloxane-ethylene copolymers,
polysiloxane-alkylenesilane copolymers, polysiloxaneethyl

amount of an opioid antagonist selected from the group

nalmefene, cyclaZocine, Wherein the opioid antagonist is
derived from a prodrug selected from the group consisting

of, but not limited to naltrexone-R (I), nalbuphine-R,R1 (II),
55

enesilane copolymers, cellulose polymers, methyl cellulose,
ethyl cellulose, hydroxypropyl methyl cellulose, cellulose
esters, polycarbonates, polytetra?uoroethylene, starches,

(I)

gelatins, natural gums, synthetic gums, and combinations
thereof.

FIG. 2 depicts FIG. 1 after forming a prodrug imperme
able barrier 25 betWeen the surface 3 of the prodrug per

meable adhesive layer 20 and the prodrug impermeable
polymer ?lm 2. The drug impermeable barrier 25 may be
made from drug impermeable materials that include

polyethylene, polypropylene, ethylene/propylene

nalorphine-R,R1 (III), naloxone-R (IV), nalmefene-R (V),
cyclaZocine-R (VI), having the, folloWing formulas:

65
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5

of an opioid antagonist selected from the group consisting of

-continued

levallorphan, cyclorphan, oxilorphan and pentaZocine

(11)

Wherein substitution of a hydroxyl group in levallorphan has

resulted in levallorphan-R (VII), in cyclorphan has resulted
in cyclorphan-R (VIII), in oxilorphan has resulted in
oxilorphan-R (IX), and in pentaZocine has resulted in
pentaZocine-R (X), and Wherein R is physiologically hydro
lyZable and has been selected from, but not limited to,
10

alkylcarbonyl, arylcarbonyl, alkyloxycarbonyl,
aryloxycarbonyl, carbamoyl, succinyl phosphate, pivalyl
and combinations thereof. When R includes an alkylcarbo

(III)

nyl group, the alkylcarbonyl group further comprises acetyl,

propionyl, valeroyl, pentanoyl, hexanoyl, heptanoyl,
isobutyroyl, 2-ethylbutryoyl and 2-propylpentanoyl and
15

combinations thereof. When R includes a carbamoyl group,

the carbamoyl group further comprises N,N-diethyl-amino

carbamoyl, N-butyl-amino-carbamoyl, N,N-propyl-amino
carbamoyl, N-hexyl-amino-carbamoyl, N-heptyl-amino
carbamoyl and N-octyl-amino-carbamoyl and combinations
thereof.

(IV)

Results

25

Opioid antagonists such as naltrexone do not have the
essential physicochemical properties that Would alloW an
effective dose of the opioid antagonists to cross the human
skin barrier. Hereinafter the term “physicochemical prop
erty” means a property that includes both physical and

chemical phenomena. The prodrugs of the present invention
represented by chemical structures (I)—(VI) supra are more

skin permeable and rapidly converted to their opioid antago

(V)

nist analogues by physiological hydrolysis.
35

The effect of transdermal delivery of the prodrug of
structure (I), Wherein R is valeroyl (Val-NTX) is depicted in
FIG. 3 and associated discussion under In Vitro Diffusion

Studies in Example 1 infra. FIG. 3 depicts the accumulation
in micrograms (ug) of naltrexone (NTX) in a receiver
compartment of a diffusion cell When a saturated solution at

32° C. of Val-NTX 50 or NTX 60 Was passed through human
skin. NTX amounts Were measured at 6 hour intervals for 48

(VI)

hours. Further, FIG. 3 depicts about an eight-fold increase in

the amount of NTX produced by physiological hydrolysis
45

and wherein R and R1 are physiologically hydrolyZable and
are selected from, but not limited to, alkylcarbonyl,

The lipophilic prodrugs such as Val-NTX and Hep-NTX

arylcarbonyl, alkyloxycarbonyl, aryloxycarbonyl,

provide a higher ?ux of naltrexone across the skin than

carbamoyl, succinyl phosphate, pivalyl and combinations
thereof. When either R or R1 include an alkylcarbonyl
group, or When both include an alkylcarbonyl group, the

When the prodrug Val-NTX Was transdermally delivered
through the skin sample into the receiver compartment of the
diffusion cell compared to the amount of NTX delivered
When naltrexone Was transdermally delivered through the
skin sample. The data in FIG. 3 represent the meanione
standard deviation of three cells With naltrexone in the donor
compartment and four cells With Val-NTX prodrug in the
donor compartment, using human skin from one individual.

naltrexone base (One-Way AN OVA, p<0.01). The Hep-NTX

alkylcarbonyl group further comprises acetyl, propionyl,

prodrug exhibits a trend toWards providing more ?ux
enhancement than the Val-NTX prodrug, an eight-fold aver

valeroyl, pentanoyl, hexanoyl, heptanoyl, isobutyroyl,

age increase in the ?ux enhancement ratio versus a four-fold

2-ethylbutryoyl and 2-propylpentanoyl and combinations

average increase for Val-NTX. The ?ux enhancement ratios
should not be limited to the 13:1 ratio in FIG. 4, but may be
substantially greater. Table 1 infra lists the relative concen

55

thereof. When either R or R1 include an alkylcarbonyl
group, or When both include a carbamoyl group, the car

trations (umol/gram skin) of NTX, Wherein physiological
hydrolysis of the prodrug having the chemical structure (I),

bamoyl group further comprises N,N-diethyl-amino

carbamoyl, N-butyl-amino-carbamoyl, N,N-propyl-amino
carbamoyl, N-hexyl-amino-carbamoyl, N-heptyl-amino

supra, Wherein R is valeroyl (Val-NTX) or heptanoyl (Hep
NTX) results from transdermal delivery of NTX through the

carbamoyl and N-octyl-amino-carbamoyl and combinations
thereof.

Alternatively, the present invention is a method compris
ing the step of: transdermally delivering an effective amount

65

skin. The mean molar percentage of regenerated naltrexone
to total drug extracted from the skin Was about 31—38% for

Val-NTX and Hep-NTX.

US 6,569,449 B1
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7

group that promotes aqueous solubility through hydrogen

bonding.

TABLE 1
Relative Concentrations (‘umol/gram skin) of NTX:Prodrug From In

TABLE 3

Vitro Diffusion Studies.

Drug Treatment

NTX ,umol/g skin, (%)

Prodrug ,umol/ g skin

0.651, 31
1.426, 38

1.08
2.29

Val-NTX

Hep-NTX

Physicochemical Properties of Naltrexone and Its Ester Prodrugs.
Experimental Values ShoWn With Standard Deviations Are the Means
of at Least TWo Determination

10

Table 1 supra lists relative concentrations (,umol/gram skin)
of NTXzprodrug from in vitro diffusion studies. Associated
Drug

from prodrug/NTX ?ux) for each subject’s sample of skin

0.36

15

tested. Since human skin exhibits Wide inter-subject perme
ation variability, this ?ux enhancement ratio is a good Way
to compare the effect of the prodrug versus NTX, Within
each individual skin sample. Using the method for calcu
lating a mean ?ux enhancement ratio described infra in

log Pb log Pb

NTX
Val-NTX

Hep-NTX

Phosphate

Mineral

Buffer

Oil
Solubility
Solubility pH 7.4
15‘ order
32° C.,
32° C.,
32° C., pH7.4

Cal- Expericulated“ mental

text in Example 1 under In Vitro Diffusion Studies describe
calculation of a prodrug ?ux enhancement ratio (NTX ?ux

Light

(mmol/L) (mmol/L) tl/2 (hr)

0.67 r

0.258 r

15.2 1

No degradation

0.02

0.012

1.6

seen in 10 days

1.95

1.77 r

9.62 r

0.593 r

96 r 10

3.01

0.10
Not
available

0.024
Not
available

0.002
0.180 r
0.030

103 r 17

20 “calculated from Daylight ® 4.51 SoftWare

Example 1, the mean ?ux enhancement ratio for the Val

blog P = log octanol/Water partition coef?cient

NTX experiments is 4.4115 (one standard deviation), and

The octanol/Water partition coefficient increased logarithmi

an increased mean ?ux enhancement ratio of 8314.6 (one

cally With the addition of the valeryl chain, as seen in Table

standard deviation) is calculated for the Hep-NTX data.

3.

Skin esterases are quite resistant to the stresses of freezing

25

Use of Daylight® 4.51 Software enabled calculation of

and storing, Which is Why prodrug is converted in the frozen

log P (clogP) values for Naltrexone, and ester and carbamoyl

skin experiments. In fact, the enzymatic stability studies

prodrugs listed infra in Table 4.

Were done in previously frozen tissue samples, and a rapid
enzymatic conversion rate Was observed in these experi
ments. The rapid enzymatic conversion rate of the Val-NTX
is a positive attribute for drug delivery, as the active drug

Would be quickly released in the body after crossing the
skin.
The prodrugs’ melting points Were measured, as this
physicochemical property is often easily related to the
prodrugs’ solubilities (Stinchcomb et al., A Solubility and

TABLE 4
30

Calculated LOG P (clog P) of Naltrexone and Its Ester and

Carbamovl Prodrugs.
MW
35

Related Physicochemical Property Comparison of
Buprenorphine and its 3-alkyl Esters, Pharm. Res., 12,
1526—1529 (1995). Hereinafter the term “physicochemical
property” means a property that includes both physical and

40

chemical phenomena. The doWnWard trend in melting points
as a function of increasing alkyl chain length can be seen
infra in Table 2.

clogP

Ester-R-group
—H

341

.355

—COCH3
—COCH2CH3
—COCH2CH2CH3
—CO(CH2)3CH3
—CO(CH2)4CH3
—CO(CH2)5CH3
—COCH2CH(CH3)2
—COCH(CH2CH3)2
—COCH(CH2CH2CH3)2

383
397
411
425
439
453
425
439
467

.361
.890
1.419
1.948
2.477
3.006
1.821
2.257
3.318

440
440
468
468
481
495

1.36
1.67
2.42
2.73
3.26
3.79

Carbamate Ester-R-Group
45

TABLE 2
Molecular Weights (MW), and Melting Points (MP) of Naltrexone and
its Ester Prodru_gs.

Drug

R-group

MW

MP (° C.)

NTX

—H

341

166-169

VAL-NTX
HEP-NTX

—CO(CH2)3CH3
—CO(CH2)5CH3

425
453

83-85
58-60

50

—CON(CH2CH3)2
—CON(CH2)3CH3
—CON(CH2CH2CH3)2
—CON(CH2)5CH3
—CON(CH2)6CH3
—CON(CH2)7CH3
“Calculated from Daylight ® 4.51 SoftWare.

“Calculated log P (clog P) = log octanol/Water partition coe?icient.

By using Daylight® 4.51 Software, one skilled in the art

Table 2 supra lists Val-NTX and Hep-NTX prodrug melting
points, shoWing a decrease as the alkyl chain is extended, by

55

over 100° C. in the case of the heptyl ester. The fact that the

ester prodrugs exhibit loWer melting points than naltrexone
base strongly suggests that the added alkyl functionalities
disrupt the intra-crystalline cohesion of the drug. This crys

60

tal destabilization can have a profound effect on solubilities.

As expected, Table 2 supra lists the Val-NTX prodrug has a

loWer aqueous solubilities than naltrexone base because of
the prodrug’s lack of the free phenolic functional group, a

coef?cient for prodrugs (I)—(X) Wherein R and R1 are
physiologically hydrolyzable and are selected from, but not
limited to, the group consisting of alkylcarbonyl,

arylcarbonyl, alkyloxycarbonyl, aryloxycarbonyl and car
bamoyl and combinations thereof, Without the need for
further experimentation. In addition, Table 3 supra lists the
log octanol/Water partition coef?cients for Val-NTX and

Hep-NTX prodrugs, Wherein the log octanol/Water partition

higher oil (nonpolar) solubility than the parent drug.
Table 3 infra lists inter alia Val-NTX and Hep-NTX
aqueous solubilities, Wherein the prodrugs exhibit much

could calculate log P (clog P)=log octanol/Water partition

coef?cient is from about 1 to about 4. Based on the In Vitro
65

Diffusion Studies described infra in Example 1, the data
listed in Table 2 supra supporting the 8-fold ?ux enhance
ment ratio When the source of the naltrexone Was Hep-NTX
and the 4-fold ?ux enhancement ratio When the source of

US 6,569,449 B1
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naltrexone Was Val-NTX, and FIG. 3, supporting the 8-fold
increased cumulative amount of naltrexone transdermally
delivered through the skin, one skilled in the art could

1 ml methylene chloride and triethylamine (50 ml, 0.7
mmol). The solution Was placed in an ice bath and stirred.

reasonably make and use the present invention to treat

moiety, or a solution thereof in methylene chloride, Was

The acid chloride (0.15 mmol) of the desired prodrug

alcohol and narcotic dependence, according to the embodi

added dropWise. After addition Was complete, the reaction

ments of the present invention.

mixture Was alloWed to Warm up to room temperature and

Prodrug chemical stability to hydrolysis Was monitored in
pH 7.4 phosphate buffer at 32° C. The prodrugs hydrolyZed
in the buffer in an apparent ?rst-order fashion; therefore
plots Were made of the natural logarithm of concentration

stirred for an additional 4 hrs. The progress of the reaction
10

depletion as a function of time. The observed half-lives
calculated using the curves from these plots are summariZed

infra in Table 1. The slopes of the curves, Which are equal
to the rate constant, Were determined using linear regression
analysis. None of the coef?cients of determination for the
lines Were less than 0.95. The half-lives Were calculated by
dividing 0.693 by the individual rate constants. All chro

Were sprayed With 10% HZSO4 in ethanol and heated at 100°
C. for 5 min. NTX and its Prodrugs Were detected as broWn
15

In almost all cases, the prodrugs Were completely hydro
lyZed on passing through the skin and appeared as naltrex
one in the receiver compartment. Therefore, plots of the
cumulative amounts of NTX permeated through human skin

spots With typical Rf values (eg NTX=0.4 and Val-NTX=
0.6). After completion of the reaction, the methylene chlo
ride solution Was Washed With 10% aqueous sodium car

bonate and then With Water, dried over anhydrous sodium

matograms from the degradation experiments shoWed an
increasing naltrexone peak as the prodrug Was depleted. The
prodrug hydrolysis reactions Were carried out to at least four
half-lives.
In Vitro Diffusion Studies

Was folloWed With thin layer chromatography (TLC): small
samples (10 ml) of the reaction mixture Were spotted on
silica gel plates and developed in an n-butanol:acetic acid:
Water (10:1:1) cosolvent system. After drying, the plates

sulfate, ?ltered, and reduced to a small volume on a rotary
20

evaporator. The esters Were precipitated by adding excess
petroleum ether and the desired product Was ?ltered off and
dried on air. Purity Was checked by reversed-phase HPLC

With UV-detection (230 nm) using a Water-acetonitrile gra
25

dient (0—100% acetonitrile in 20 min.) on a C18 analytical
column. If the purity Was less than 95%, the compounds

Were further puri?ed by preparative HPLC. The ?nal prod

over time from saturated mineral oil solutions of either a

ucts Were characteriZed by 1H-nuclear magnetic resonance

prodrug or naltrexone base Were constructed for data analy

spectroscopy (NMR, IBM FTNMR NR/250) and mass spec

sis. A representative NTX permeation pro?le is shoWn FIG.
3. Steady-state ?uxes and lag times calculated using the

trometry. Val-NTX m/e Was 425.22. Hep-NTX m/e Was
30

453.25. Val-NTX, 1H NMR (DMSO-d6): d 0.16—0.53 (m,

and 4, respectively.

5H, cyclopropyl), 0.96 (t, 3H, CH3), 1.3—3.4 (m, 20H,
aliphatic), 4.85 (s, 1H, C-5) 6.31—6.62 (2d, 2H, aromatic);

“Lag times” Which hereinafter mean the delay before
detectable naltrexone appears in the receiver compartment
of the diffusion cell due to physiological hydrolysis of
Val-NTX or Hep-NTX are depicted in FIG. 4. The data

(m, 5H, cyclopropyl), 0.91 (t, 3H, CH3), 1.3—1.59 (m, 8H,
aliphatic), 2.19—2.94 (m, 8H, aliphatic), 4.85 (s, 1H, C-5)
6.31—6.62 (2d, 2H, aromatic); C27H35NO5.

terminal, linear regions of the curves are shoWn in FIGS. 3

C25H31NO5. Hep-NTX, 1H NMR (DMSO-dG): d 0.19—0.47
35

represents the mean +/— one standard deviation of three cells

With naltrexone in the donor compartment and four cells
With saturated solutions of Val-NTX or Hep-NTX in the
donor compartment, using human skin from one individual.
The skin donor age, sex, and skin sample storage condition
are shoWn for each experiment. F=female and M=male.

The HPLC system consisted of a Waters 717
40

column (and guard column) Were used With the UV detector
set at a Wavelength of 215 nm. The mobile phase consisted

Previously froZen skin samples (7—12 months) are indicated

of 0.1% tri?uoroacetic acid (adjusted to pH 3 With

by frZ, and samples used fresh are indicated by frsh. *Iso

tonic phosphate buffer, pH=7.4. **HEPES-buffered Hanks

45

balanced salts solution.
Example 1 infra describes in vitro diffusion studies With

human skin using the prodrug material (I), Wherein R is a
valeryl group (Val-NTX) and Wherein R is a heptanoyl
group (Hep-NTX), to determine the level of opoid antago
nist transdermal delivery enhancement. In Example 1, Val

Autosampler, 501 Pumps, and a 484 Tunable UV Absor
bance Detector With Millennium Chromatography SoftWare.
A reversed phase 22-cm BroWnlee C-18 Spheri-5 micron

triethylamine): acetonitrile: sodium heptane sulfonate (300
mL:700 mL:0.3 g) at a How rate of 1.5 mL/min. One
hundred microliters of sample Were injected onto the col
umn. Standard curves exhibited excellent linearity over the

entire concentration range employed in the assays. The assay
sensitivity Was 10 ng/mL.
50

The prodrug materials Val-NTX and Hep-NTX Were

isolated from the buffer samples by solid-phase extraction

NTX and Hep-NTX are more skin permeable than naltrex
one (NTX) and are rapidly converted to the respective

(Oasis HLB, Waters Corp., Milford, Mass.). The solid-phase

opioid antagonist in the viable skin layers.

extraction cartridge Was pretreated With one milliliter of
methanol and one milliliter of Water before the aqueous drug

55

sample Was run through the cartridge. After running the
sample through the cartridge, the sample Was Washed With

EXAMPLE 1

Naltrexone (NTX) base Was purchased from Mallinckrodt
Inc., St. Louis, M0. The prodrug Were synthesiZed directly
from naltrexone base. The drugs’ melting points Were mea

sured on a hot-stage melting point apparatus (Fisher-Johns,
Pittsburgh, Pa.). Reagent-grade chemicals Were obtained

from Sigma Chemical Co. (St. Louis, Mo.).

Prodrug Synthesis
Val-NTX and Hep-NTX prodrug Material Were synthe
siZed by dissolving naltrexone base (50 mg, 0.13 mmol) in

one milliliter of 5% methanol/Water, and eluted With aceto

nitrile. Sample recovery Was ninety-eight percent.
60

Octanol/Water Partition Coef?cients
The octanol/Water partition coef?cients Were determined

using pH 7.4 isotonic phosphate buffer as the aqueous phase.
65 All steps Were carried out at room temperature. An appro

priate amount of drug Was Weighed into a vial and dissolved
in a knoWn amount of octanol. An equivalent amount of
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buffer Was then added to the vial and the phases shaken for

of time. The ?ux value for a given run Was calculated from

24 hours. The vials Were left undisturbed for at least one

Fick’s First LaW of diffusion, infra:

hour after shaking. An exact volume Was taken from the

aqueous phase, diluted With acetonitrile, and then analyZed
by HPLC. The ?nal pH of the aqueous phase at the end of

Formula I:

the shaking period Was 7.95. Similarly, an exact volume Was

taken from the octanol phase, diluted With acetonitrile, and
then analyZed by HPLC. Partition coef?cients Were calcu

In this equation, J5 is the steady-state ?ux in g/cmZ/h; Ais the

lated by determining the phase concentration ratios.
10

Solubilities

gradient across the membrane. Since build up in the receiver
cell Was kept to a minimum throughout the studies, the latter

The solubilities of naltrexone and its esters Were obtained

by equilibrating large excesses of each substance With the
respective vehicle, light mineral oil, or pH 7.4 isotonic
phosphate buffer at 32° C. To hasten the attainment of
equilibrium, each slurry Was continuously shaken in a sealed

area of the membrane, 0.95 cm2; P is the effective perme
ability coef?cient in cm/h; and AC is the concentration

15

is Well approximated by the donor concentration.
Drug disposition in the diffusion cell skin samples Was
measured at the end of the 48-hour experiment. The skin
sample Was removed from the diffusion cell and rinsed With

container in a shaking incubation oven. Samples Were taken,

distilled Water, in order to remove the surface formulation.
Further removal of the skin surface formulation Was accom

?ltered (mineral oil:Millex FG-13, Millipore and buffer
:glass micro?ber, Gelman) above 32° C., measured With

plished by blotting With a paper toWel, and stripping With
adhesive tape applied to the surface and quickly removed

respect to volume, and diluted With the appropriate amount
of acetonitrile. The diluted samples Were analyZed by
HPLC. The initial forty percent of each ?ltrate Was dis
carded to eliminate the possibility that adsorption of drug on

sample and minced With a scalpel. The Wet tissue Weight Was
recorded and the sample Was placed in a vial With ten
milliliters of acetonitrile. The drug Was extracted from the

tWo times. The treated area of the skin Was cut from the skin

25

the ?lter and/or the ?ltering apparatus might in?uence the
solubility determination. The sampling procedure Was

tissue by sonicating the solution for ten minutes and shaking
the vial overnight. The samples Were assayed by HPLC and
reported as mmol of drug per gram of Wet tissue Weight.
What is claimed is:

repeated at least once for each sample. Concentration versus

1. A method for delivering an effective amount of an

time plots indicated that equilibrium Was obtained in less
than 48 hours. Therefore, the equilibration times for all the

opioid antagonist selected from the group consisting of

naltrexone, nalbuphine, nalorphine, naloxone, nalmefene,
cyclaZocine, levallorphan, cyclorphan, oxilorphan and pen

studies Were 48 hours.

taZocine comprising transdermally administering an opioid

Chemical Stability
Solutions of the respective drug in pH 7.4 phosphate

antagonist prodrug selected from the group consisting of
35

buffer Were monitored over time. The solutions Were stored

in sealed vials in a 32° C. incubation oven. At appropriate

naltrexone-R (I), nalbuphine-R,R1 (II), nalorphine-R,R1
(III), naloxone-R (IV), nalmefene-R (V), cyclaZocine-R
(VI), levallorphan-R (VII), cyclorphan-R (VIII),
oxilorphan-R (IX), and pentaZocine-R (X),

time intervals, samples Were removed, isolated from the
buffer by solid-phase extraction, and stored at 4° C. until

Wherein R and R1 are physiologically hydrolyZable and are

HPLC quantitation.

alkylcarbonyl, arylcarbonyl, alkyloxycarbonyl,

independently selected from the group consisting of

aryloxycarbonyl, phosphate and carbamoyl.
In Vitro Diffusion Studies

The aim of in vitro experimentation in transdermal drug
delivery is to quantitate the penetration of a drug molecule
through the skin. Skin excised during abdominal reduction
surgery from several patients Was used for the permeation

2. The method of claim 1, Wherein transdermally deliv
ering the prodrug results in a naltrexone ?ux enhancement
45

3:1 to about 13:1.

3. The method of claim 1, Wherein the step of transder

mally delivering further comprises applying the prodrug to

studies. Skin samples Were sectioned from the excised
abdominal tissue using a Padgett dermatome set to 250 pm;

an epidermal layer of human skin.
4. The method of claim 1, Wherein the step of transder

some skin samples Were frozen at —80° C., others Were used

mally delivering further comprises applying the prodrug to

immediately. A PermeGear ?oW-through (In-Line,

an epidermal layer of animal skin.
5. The method of claim 1, Wherein R and R1 include an
alkylcarbonyl group selected from the group consisting of

Riegelsville, Pa.) diffusion cell system Was used for the
permeation studies. The receiver ?uid Was isotonic phos
phate buffer at pH 7.4 in some experiments, and in more

ratio (?ux from prodrug:?ux from naltrexone) from about
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recent experiments We sWitched to a HEPES-buffered

Hanks balanced salts solution, in order to help preserve

acetyl, propionyl, valeroyl, pentanoyl, hexanoyl, heptanoyl,
isobutyroyl, pivalyl, succinyl, 2-ethylbutryoyl and
2-propylpentanoyl and combinations thereof.

tissue viability. The How rate of the receiver ?uid Was set at

6. The method of claim 1, Wherein R and R1 include a

1 ml/hr in order to help maintain sink conditions. The drugs
Were isolated from the receiver samples by solid-phase
extraction, and stored at 4° C. until HPLC quantitation. The

carbamoyl group selected from the group consisting of

temperature of the diffusion cells Was maintained at 32° C.
With a circulating Water bath. The diffusion experiment Was

N-heptyl-amino-carbamoyl and N-octyl-amino-carbamoyl

N,N-diethyl-amino-carbamoyl, N-butyl-amino-carbamoyl,
N,N-propyl-amino-carbamoyl, N-hexyl-amino-carbamoyl,
and combinations thereof.
7. The method of claim 1, Wherein the step of transder

initiated by charging the donor compartment With 0.25 ml of

drug suspended (saturated solution) in light mineral oil.
The permeation data Were plotted as the cumulative amount
of drug collected in the receiver compartment as a function

65

mally delivering further comprises using a prodrug having a
log octanol/Water partition coefficient from about 1 to about
4.
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16. The method of claim 14 Wherein the alkylcarbonyl is

8. The method of claim 1, wherein the step of transder

valeroly.

mally delivering further comprises substantially physiologi
cally hydrolyZing R and R1.

17. The method of claim 14 Wherein the alkylcarbonyl is

heptanoyl.

9. The method of claim 7, Wherein the step of transder

mally delivering further comprises substantially physiologi

18. A method of treating alcoholism or narcotic depen
dence comprising topically administering to a patient an
effective amount of a prodrug of an opioid antagonist,
Wherein the prodrug is selected from the group consisting of

cally hydrolyZing R and R1.
10. The method of claim 1 Wherein the prodrug is
naltreXone-R, and Wherein R is an alkylcarbonyl group.
11. The method of claim 10 Wherein the alkylcarbonyl

naltreXone-R (I), nalbuphine-R,R1 (II), nalorphine-R,R1
(III), naloXone-R (IV), nalmefene-R (V), cycloZocine-R

group is valeroyl.
12. The method of claim 10, Wherein the alkylcarbonyl is

(VI), levallorphan-R (VII), cyclorphan-R (VIII),

heptanoyl.

oXilorphan-R (IX), and pentaZocine-R (X),

13. A method for enhancing the delivery of an opioid

antagonist through the skin of a patient comprising topically
administering to the patient a prodrug of the opioid

Wherein R and R1 are physiologically hydroliZable and are

independently selected from the group consisting of
15

antagonist, Wherein the prodrug is selected from the group

consisting of naltreXone-R (I), nalbuphine-R,R1 (II),
nalorphine-R,R1 (Ill), naloXone-R (IV), nalmefene-R (V),

tions thereof.
19. The method of claim 17 Wherein the prodrug is
naltreXone-R.
20. The method of claim 18 Wherein R is an alkylcarbo

cycloZocine-R (VI), levallorphan-R (VII), cyclorphan-R
(VIII), oXilorphan-R (IX), and pentaZocine-R (X),
Wherein R and R1 are physiologically hydroliZable and are

nyl.

independently selected from the group consisting of

21. The method of claim 19 Wherein the alkylcarbonyl is

alkylcarbonyl, arylcarbonyl, alkyloXycarbonyl,

valeroly.

aryloXycarbonyl, phosphate and carbamoyl.
14. The method of claim 13 Wherein the prodrug is
naltreXone-R.
15. The method of claim 13 Wherein R is an alkylcarbo

nyl.

alkylcarbonyl, arylcarbonyl, alkyloXycarbonyl,
aryloXycarbonyl, phosphate and carbamoyl and combina

25

22. The method of claim 19 Wherein the alkylcarbonyl is

heptanoyl.

